All In Biotech

Drug Trial Radar · NCT06131255

Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study

The Role of the Glutamatergic Neurotransmission in Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Aug 1, 2023

Primary completion

Jan 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 14, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Post-partum depression (PPD) is a prevalent subtype of major depressive disorder that causes a significant distress to the woman and substantial impact on the whole family. Many studies implicate the glutamatergic system in pathological processes relevant to PPD disorders. There is evidence that cell adhesion molecules (CAMs) play a key role in how glutamatergic circuits wire up during development and how glutamatergic synapses, once formed, operate. However, it is unclear how dysregulation in diverse CAMs alter glutamatergic circuitries responsible for emotional and social behavior. Here, the investigators propose to evaluate the molecular and neurobiological underpinnings of PPD focusing on CAMs at glutamatergic synapses by using an integrated approach from mouse models to human patients. Moreover, the investigators will also perform a pilot study to investigate the impact of selective antidepressants, known to be linked to CAMs, in both human and mice.

Conditions

  • Post-partum Depression

Interventions

  • CitalopramDrug

    Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total White Matter (WM) Volume at Week 12Time frame: Baseline and week 12
  2. Change From Baseline in Total Gray Matter (GM) Volume at Week 12Time frame: Baseline and week 12
  3. Change From Baseline in Total Brain Volume at Week 12Time frame: Baseline and week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico

    Milan, Michigan, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.